St. Petersburg researchers using IQVIA sales data found semaglutide grew about 329 times since 2020, and patients paid out of pocket for 89% of it.
Recap by typeshit. Full story at Новости GxP.
Researchers compared short-term glycemic response to tirzepatide in type 2 diabetes patients based on whether they had used incretin drugs before.
Part of his GLP-1 series, Krittanawong discusses whether the drugs could help MASLD and MASH, and how visceral fat can drive metabolic problems unseen.
16:32
Dr. Kevin Joseph, DO, who treats liver disease daily, shares his views on peptides. The claims are his own, not established treatment guidance.
Dr. Jonathan Stegall shares the data: about 13 in 100 GLP-1 users with stage 1 to 3 colorectal cancer saw it spread, versus about 22 in 100 on another diabetes drug.
Vomiting fell to 43% from 58.5% on placebo, and Vanda plans to seek an expanded approval for GLP-1 nausea based on the results.
The deal brings both the injectable and oral versions of Wegovy straight to employers, another move in the push for workplace GLP-1 coverage.
Loading…